Additionally, the 36-month beta value for BDTX is 2.59. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for BDTX is 38.11M and currently, short sellers hold a 5.36% ratio of that float. The average trading volume of BDTX on April 18, 2024 was 601.12K shares.
BDTX) stock’s latest price update
Black Diamond Therapeutics Inc (NASDAQ: BDTX)’s stock price has plunge by 5.95relation to previous closing price of 5.38. Nevertheless, the company has seen a 14.46% surge in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-15 that Black Diamond (BDTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
BDTX’s Market Performance
BDTX’s stock has risen by 14.46% in the past week, with a monthly rise of 21.28% and a quarterly rise of 108.79%. The volatility ratio for the week is 9.11% while the volatility levels for the last 30 days are 8.36% for Black Diamond Therapeutics Inc The simple moving average for the last 20 days is 11.10% for BDTX stock, with a simple moving average of 64.55% for the last 200 days.
Analysts’ Opinion of BDTX
Stifel, on the other hand, stated in their research note that they expect to see BDTX reach a price target of $10, previously predicting the price at $2. The rating they have provided for BDTX stocks is “Buy” according to the report published on June 30th, 2023.
H.C. Wainwright gave a rating of “Buy” to BDTX, setting the target price at $11 in the report published on June 28th of the previous year.
BDTX Trading at 19.85% from the 50-Day Moving Average
After a stumble in the market that brought BDTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -16.79% of loss for the given period.
Volatility was left at 8.36%, however, over the last 30 days, the volatility rate increased by 9.11%, as shares surge +23.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +43.22% upper at present.
During the last 5 trading sessions, BDTX rose by +14.46%, which changed the moving average for the period of 200-days by +12.87% in comparison to the 20-day moving average, which settled at $5.18. In addition, Black Diamond Therapeutics Inc saw 102.85% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BDTX starting from BIOTECH GROWTH N V, who purchase 400,000 shares at the price of $2.34 back on Oct 17 ’23. After this action, BIOTECH GROWTH N V now owns 8,517,839 shares of Black Diamond Therapeutics Inc, valued at $934,080 using the latest closing price.
Behbahani Ali, the Director of Black Diamond Therapeutics Inc, purchase 1,000,000 shares at $5.00 during a trade that took place back on Jul 05 ’23, which means that Behbahani Ali is holding 4,448,757 shares at $5,000,000 based on the most recent closing price.
Stock Fundamentals for BDTX
The total capital return value is set at -0.62. Equity return is now at value -70.94, with -52.37 for asset returns.
Based on Black Diamond Therapeutics Inc (BDTX), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at -2.64. The debt to equity ratio resting at 0.22. The interest coverage ratio of the stock is 126.03.
Currently, EBITDA for the company is -86.02 million with net debt to EBITDA at 0.36. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.82.
Conclusion
In conclusion, Black Diamond Therapeutics Inc (BDTX) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
